Alpha 1 Biomedicals Inc. (NASDAQ:ALBM) of Bethesda, Md., announced that StanfordUniversity researchers will initiate a pilot clinical study of its drug, Thymosis alpha 1,in combination with AZT and PEG-IL-2 for treating AIDS patients whose CD4 cell count isbetween 100 and 200. The study is intended to determine the combination therapy’ssafety as well as the ability of the combination to enhance CD4 and T cell counts.